SC83288 is a clinical development candidate for the treatment of severe malaria.
about
Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria.Profiling molecular factors associated with pyknosis and developmental arrest induced by an opioid receptor antagonist and dihydroartemisinin in Plasmodium falciparum.Humanized mouse models infected with human Plasmodium species for antimalarial drug discovery.Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum.Drugs in Development for Malaria.Recent updates in the discovery and development of novel antimalarial drug candidates
P2860
SC83288 is a clinical development candidate for the treatment of severe malaria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SC83288 is a clinical development candidate for the treatment of severe malaria.
@en
SC83288 is a clinical development candidate for the treatment of severe malaria.
@nl
type
label
SC83288 is a clinical development candidate for the treatment of severe malaria.
@en
SC83288 is a clinical development candidate for the treatment of severe malaria.
@nl
prefLabel
SC83288 is a clinical development candidate for the treatment of severe malaria.
@en
SC83288 is a clinical development candidate for the treatment of severe malaria.
@nl
P2093
P2860
P50
P356
P1476
SC83288 is a clinical development candidate for the treatment of severe malaria
@en
P2093
Cecilia P Sanchez
Dominique Mazier
Henri J Vial
Leonardo Lucantoni
Maëlle Duffey
Roland Baumgartner
Roman Rösemann
Stefan Strobl
Stefanie K Fehler
Stefano Pegoraro
P2860
P2888
P356
10.1038/NCOMMS14193
P407
P577
2017-01-31T00:00:00Z